Baxter International (NYSE:BAX) has tumbled 0.11% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 3.54% in the last four weeks. In the past week, the company has outperformed the S&P 500 by 1.09% and the outperformance has advanced to 2.6% for the last 4 weeks period.
Baxter International (NYSE:BAX): The stock opened at $44.63 on Friday but the bulls could not build on the opening and the stock topped out at $44.67 for the day. The stock traded down to $44.00 during the day, due to lack of any buying support eventually closed down at $44.44 with a loss of -0.29% for the day. The stock had closed at $44.57 on the previous day. The total traded volume was 5,158,086 shares.
The company shares have rallied 16.83% from its 1 Year high price. On May 12, 2016, the shares registered one year high at $46.95 and the one year low was seen on Oct 6, 2015. The 50-Day Moving Average price is $44.34 and the 200 Day Moving Average price is recorded at $40.26.
On the companys insider trading activities, Almeida Jose E, CEO of Baxter International Inc, had purchased 11,691 shares on May 23, 2016. The total value of the transaction was $499,790. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Many analysts have stated their opinion on the company shares. Evercore ISI Group initiates coverage on Baxter International (NYSE:BAX) . Analysts at the Evercore ISI Group have a current rating of Buy on the shares. The rating by the firm was issued on May 4, 2016. Currently the company Insiders own 1.08% of Baxter International shares according to the proxy statements. Institutional Investors own 84.39% of Baxter International shares. During last six month period, the net percent change held by insiders has seen a change of -23.18%.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.